Novel intergenic KIF5B-MET fusion variant in a patient with gastric cancer: A case report

BACKGROUND: MET fusion is a key driver mutation, but it is rare in gastric cancer (GC). Several MET (hepatocyte growth factor receptor) inhibitors have been approved for the treatment of MET-positive patients, but the tumor response is heterogeneous. With the development of next-generation sequencin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhi-Wei, Sha, Yu, Chen, Qing, Hou, Juan, Sun, Yan, Lu, Wang-Kun, Chen, Jing, Yu, Li-Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107910/
https://www.ncbi.nlm.nih.gov/pubmed/34002144
http://dx.doi.org/10.12998/wjcc.v9.i14.3350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107910/
https://www.ncbi.nlm.nih.gov/pubmed/34002144
http://dx.doi.org/10.12998/wjcc.v9.i14.3350

Ejemplares similares